Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, have announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also known as STAR-001, in patients with recurrent glioblastoma (GBM). The study, published in the October 2026 issue of Cancer Research Communications, evaluated 16 patients and found that LP-184 was generally well tolerated, establishing a recommended expansion dose of 0.39 mg/kg.
No objective radiographic responses were observed, but one patient remained clinically and radiographically stable for more than 22 months after enrollment. The findings also identified limited drug exposure in brain tumors, which supports further evaluation of LP-184 in combination with spironolactone, an FDA-approved drug that reduced the concentration of LP-184 needed to kill GBM cells by threefold to sixfold in preclinical models.
According to the company, these findings establish a dosing rationale for a planned Phase 1b/2a trial evaluating LP-184 plus spironolactone in patients experiencing their first GBM recurrence. The study, sponsored by Starlight Therapeutics under an FDA-cleared Investigational New Drug application, will assess safety, pharmacokinetics, and objective response. The combination strategy was developed with support from Lantern’s RADR® AI platform and research collaborators at Johns Hopkins University.
LP-184 has received FDA Fast Track Designation for GBM and triple-negative breast cancer, along with Orphan Drug Designations for certain central nervous system cancers. The full press release is available at https://ibn.fm/qaLVQ.
Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For investors, the publication of Phase 1a data and the advancement toward a Phase 1b/2a trial represent a key milestone for Lantern’s lead candidate in GBM, a devastating cancer with limited treatment options. The combination approach with spironolactone, if successful, could offer a new therapeutic strategy for patients facing their first recurrence. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
The announcement was distributed through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For more information, visit MissionIR.
